The applicable role of upregulated LSD1 in AML has been validated by the linked outcomes attained in a cytogenetically distinct subtype of AML, the APL, described by a translocation containing promyelocytic leukemia gene, PML and the retinoic acid receptor, RARα genes. The gene discussed is KDM1A; the disease is leukemia.